National Graphite (NGRC) Stock Overview
Through its subsidiary, Biotech Development Corp., operates as a biopharmaceutical risk/cost-sharing company. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
NGRC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
National Graphite Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.022 |
| 52 Week High | US$0.078 |
| 52 Week Low | US$0.016 |
| Beta | 0 |
| 1 Month Change | 16.84% |
| 3 Month Change | 5.71% |
| 1 Year Change | -30.84% |
| 3 Year Change | -78.34% |
| 5 Year Change | -63.31% |
| Change since IPO | -99.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| NGRC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -49.5% | -0.9% | -0.3% |
| 1Y | -30.8% | 26.9% | 15.4% |
Return vs Industry: NGRC underperformed the US Biotechs industry which returned 26.9% over the past year.
Return vs Market: NGRC underperformed the US Market which returned 15.4% over the past year.
Price Volatility
| NGRC volatility | |
|---|---|
| NGRC Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NGRC's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine NGRC's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | Ulrike Dickmann | n/a |
National Graphite Corp., through its subsidiary, Biotech Development Corp., operates as a biopharmaceutical risk/cost-sharing company. The company collaborates with clinical stage companies that develop new biological entities or new therapeutically platforms for the treatment of various diseases, rare diseases, and diseases with unmet needs. It is developing a drug candidate called ELAFIN, which is a human identic protein for the treatment of postoperative inflammatory complications.
National Graphite Corp. Fundamentals Summary
| NGRC fundamental statistics | |
|---|---|
| Market cap | US$3.43m |
| Earnings (TTM) | -US$1.97m |
| Revenue (TTM) | n/a |
Is NGRC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NGRC income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$1.97m |
| Earnings | -US$1.97m |
Last Reported Earnings
May 31, 2015
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did NGRC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/19 09:11 |
| End of Day Share Price | 2026/01/16 00:00 |
| Earnings | 2015/05/31 |
| Annual Earnings | 2015/05/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
National Graphite Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.